CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Bristol Myers Squibb CO (BMY) / deucravacitinib
Forward catalyst · BMY

deucravacitinib

Sponsor Bristol Myers Squibb CO · listed as BMY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

deucravacitinib is a clinical-stage drug asset sponsored by Bristol Myers Squibb CO, listed as BMY. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Jul 25, 2026 (day precision, medium confidence), tied to trial NCT04036435. The asset is in Phase 3 and currently active not recruiting, studied in Psoriasis. It appears across 12 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-07-25
As disclosedJul 25, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT04036435
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorBristol-Myers Squibb
Listed asBMY
Condition(s)Psoriasis

All tracked catalysts for deucravacitinib

DateEventConfidenceTrial
2026-07-25READOUTmediumNCT04036435
2026-10-19READOUTmediumNCT05617677
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More BMY catalysts